NFKB1 and carcinoma: In the previous research regarding tamoxifen and inflammation, Chuang et al. [18] investigated the baseline levels of NF-κB activity of representative carcinoma cell lines, and the change of NF-κB activity in response to a challenge with tamoxifen treatment.